Abstract: The invention relates to adeno-associated virus (AAV) serotype AAV-Rh74 and related AAV vectors, and AAV-Rh74 and related AAV vector mediated gene transfer methods and uses. In particular, AAV-Rh74 targets polynucleotides to cells, tissues or organs for expression (transcription) of genes encoding therapeutic proteins and peptides, and polynucleotides that function as or are transcribed into inhibitory nucleic acid sequences.

Abstract: Described are methods and systems comprising providing an energy hub having an electrical infrastructure; providing a number of generators of electrical energy and a plurality of consumers of electrical energy connectable to and disconnectable from said electrical infrastructure, the plurality of consumers comprising at least one critical consumer of electrical energy and at least one non-critical consumer of electrical energy; disconnecting the energy hub from the grid; supplying said electrical infrastructure with electrical energy from at least some generators among said number of said generators of electrical energy; using said electrical energy by means of at least some consumers of said plurality of consumers; monitoring at least voltage and frequency of said electrical energy in said electrical infrastructure; and selectively disconnecting and/or reconnecting one or more of said non-critical consumers of electrical energy.

Abstract: The invention relates to pyridone amide compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human in need thereof, wherein the methods and uses comprise conjointly administering N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) and an antiseizure medication (ASM) to the human in amounts that are therapeutically effective when conjointly administered. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

Abstract: Described are systems and methods for black-starting an electrical grid, comprising disconnecting an energy farm from the grid at a first location, said first location being located between the electrical grid and the energy storage with the associated converter, providing a synchronous condenser, energizing the AC export cable using said energy storage and the associated converter, energizing at least one part of the energy farm electrical infrastructure via said AC export cable using said energy storage and the associated converter, re-establishing energy supply to said energy farm electrical infrastructure by said electric generators, energizing said synchronous condenser, and reconnecting the energy farm to said electrical grid at said first location.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Abstract: A health risk evaluation system may manage, for a set of users, a corresponding set of digital healthcare profiles, where each digital healthcare profile includes a healthcare decision tree; determine, for a first user, a first subset of the users with a first set of similar digital healthcare profiles based on the corresponding set of healthcare decision trees; determine, based on correlation between a first healthcare decision tree with the first set of healthcare decision trees, a first recommended action; provide information related to the first recommended action; update, for a second user, a second digital healthcare profile and healthcare decision tree; determine the updated second healthcare decision tree deviates from the first set of healthcare decision trees; removing, based on the determined deviation, the second user from the users; determine, based on the updated first set of digital healthcare profiles, a second recommended action; and provide information related to the second recommended actio

Abstract: The invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: (I). The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Abstract: A health risk evaluation system may manage, for a set of users, a corresponding set of digital healthcare profiles, where each digital healthcare profile includes a healthcare decision tree; determine, for a first user, a first subset of the set of users with a first set of similar digital healthcare profiles based on the corresponding set of healthcare decision trees; determine, for the first user, a second subset of the set of users that are associated with the first user based on a social relationship between the first user and each user in the second subset of users; determine, based on the first set of digital healthcare profiles of the first subset of users and the second set of digital healthcare profiles of the second subset of users, a first recommended action for the first user; and provide, to the first user, information related to the first recommended action.

Abstract: Described herein are systems and methods for receiving healthcare data from a plurality data sources that generate and store data in various data model regimes, many of which are not standardized or are variants of a standard. The stored data may then be used to provide a plurality of customized execution environments and graphical user interfaces (GUIs) to users, based on each user's electronic healthcare records, insurance records, and wearable device data.

Abstract: In certain embodiments, the present disclosure is directed to methods for treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Abstract: Described herein are systems and methods for receiving healthcare data from a plurality data sources that generate and store data in various data model regimes, many of which are not standardized or are variants of a standard. The stored data may then be used to provide a plurality of customized execution environments and graphical user interfaces (GUIs) to users, based on each user's electronic healthcare records, insurance records, and wearable device data.

Abstract: The invention relates to pyridone amide compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Abstract: The invention relates to pyridone amide compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.

Abstract: This invention is directed to methods of preparing benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Abstract: The invention relates to pyridone amide compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.